3 results
Approved WMORecruiting
To evaluate the long-term safety of zanubrutinib in patients with B-cell cancers who participated in a BeiGene parent study for zanubrutinib
Approved WMOCompleted
The primary objective of the study is to determine the proportion of patients with elevated TGs, without Familial ChylomicronemiaSyndrome (FCS) due to loss of function (LoF) mutations in lipoprotein lipase (LPL), and a history of…
Approved WMORecruiting
All primary and secondary objectives will compare zanubrutinib (also known as BGB-3111) plus rituximab followed by zanubrutinib monotherapy versus bendamustine plus rituximab followed by observation only.Primary:• To compare efficacy, as measured by…